Iovance Biotherapeutics (NASDAQ: IOVA) is a promising biotech stock due to its unique cell therapy for melanoma, Amtagvi. However, profitability may be a long-term goal, and the company faces challenges in manufacturing efficiency and regulatory approvals for expansion.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing